Clofarabine in leukemia

Expert Review of Hematology

Volumn 3, Issue 1, 2010, Pages 15-22

  Ghanem, Hady ^a   Jabbour, Elias ^b   Faderl, Stefan ^b   Ghandhi, Varsha ^b   Plunkett, William ^b   Kantarjian, Hagop ^b  

^a Box 428 ^*  (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Clofarabine; Hematologic malignancy; Nucleoside analog; Solid tumors

Indexed keywords

CLADRIBINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEOXYCYTIDINE KINASE; DNA POLYMERASE; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MITOXANTRONE; RIBONUCLEOTIDE REDUCTASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BILIRUBIN BLOOD LEVEL; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DEATH; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG STABILITY; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; LIVER DYSFUNCTION; LOW DRUG DOSE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SOLID TUMOR;

ADENINE NUCLEOTIDES; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; CLINICAL TRIALS AS TOPIC; CYTARABINE; DRUG THERAPY, COMBINATION; HUMANS; LEUKEMIA; LYMPHOPROLIFERATIVE DISORDERS;

EID: 77953447199     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.70     Document Type: Review

References (42)

1. Parker WB, Allan PW, Hassan AE et al. Antitumor activity of 2-fluoro-2- deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther. 10, 23-29 (2003).
2. Carson DA, Wasson DB, Esparza LM et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro 2-arabino-fluoro-2 deoxyadenosine. Proc. Natl Acad. Sci. USA 89, 2970-2974 (1992).
3. Lotfi K, Mansson E, Spasokoukotskaja T et al. Biochemical pharmacology and resistance to 2-chloro-2́-arabino-fluoro- 2'deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin. Cancer Res. 5, 2438-2444 (1999).
4. Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2- fluoro-d-arabinofuranosyl) adenine in human lymphoblastoid cells. Cancer Res. 55, 2847-2852 (1995).
5. Pui CH, Jeha S. Clofarabine. Nat. Rev. Drug Discov. Suppl. S12--S13 (2005).
6. Parker WB, Shaddix SC, Chang CH et al. Effects of 2-chloro-9-(2-deoxy-2- fluoro-b-darabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by it 5́-triphosphate. Cancer Research 51, 2386-2394 (1991).
7. Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2- deoxy-fluoro-d-arabinofuranosyl) adenine. Cancer Res. 56, 3030-3037 (1996).
8. Genini D, Adachi S, Chao Q et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 96, 3537-3543 (2000).
9. Parker WB, Shaddix SC, Rose L et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-d-arabinofuranosyl) adenine, 2-chloro-9-(2- deoxy-2-fluoro-b-darabinofuranosyl) adenine, 2-chloro-9-(2-deoxy- 2, 2-difluoro-d-ribofuranosyl) adenine in CEM cells. Mol. Pharmacol. 55, 515-520 (2000).
10. Parker WB, Bapat AR, Shen JX et al. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol. Pharmacol. 34, 485-491 (1988).
11. Parker WB, Shaddix SC, Chang CH et al. Effects of 2-chloro-9-(2-deoxy-2- fluoro-d-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5-triphosphate. Cancer Res. 51, 2386-2394 (1991).
12. Takahashi T, Kanaqawa J, Akinaga S et al. Antitumor activity of 2-chloro-9-(2-deoxy-fluoro-b-d-arabinofuranosyl)adenine, a novel deoxyadenosine analog magainst human colon tumor xenografts by oral administration. Cancer Chemother. Pharmacol. 43, 233-240 (1999).
13. Southern Research Institute. Response of Subcutaneous HT-29 Colon Tumor to Clofarabine or CPT-11 (Final Report ILEX-27). 17 April 2003.
14. Southern Research Institute. Response of Subcutaneous CCRF-CEM Leukemia to Combination Treatment with Ara-C and Clofarabine (Final Report ILEX-12). 26 February 2003.
15. Waud WR, Schmid SM, Montgomery JA, Secrist JA 3rd. Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-b-d-arabinofuranosyl) adenine (Cl-F-ara-A). Nucleosides Nucleotides Nucleic Acids 19, 447-460 (2000).
16. Genzyme Corp. Clofarabine Investigator's Brochure. 6th Edition. Final report. San Antonio, TX, USA 15 March 2007.
17. Avramis VI, Plunkett W. Metabolism of 9-6-d-arabinosyl-2fluoroadenine-41- phosphate by mice bearing P388 leukemia. Cancer Drug Deliv. 1, 1-10 (1983).
18. Kantarjian H, Gandhi V, Kozuch P et al. Phase I clinical and pharmacology study of clofarabine (CI-F-ara-A; 2 chloro-2-fluoro-deoxy-9-b- darabinofuranosyladenine) in patients with solid and hematologic cancers. J. Clin. Oncol. 21, 1167-1173 (2003).
19. Gandhi V, Kantarjian H, Faderl S et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin. Cancer Res. 9, 6335-6342 (2003).
20. Kantarjian H, Gandhi V, Cortes J et al. Phase 2 clinical or pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102, 2379-2386 (2003).
21. Bonate P. Pharmacokinetic analysis of patients enrolled in study CLO-152 (a Phase I, dose escalation and pharmacokinetic study of oral clofarabine administered daily for 5 days in adult patients with refractory solid tumors) and interim pharmacokinetic analysis of patients enrolled in study CLO-151 (a Phase I and pharmacokinetic study of clofarabine in adult patients with advanced solid tumors). Final report 13 October 2006.
22. Gandhi V, Plunkett W. Modulation of arabinosyl nucleoside metabolism by arabinosyl nucleotides in human leukemia cells. Cancer Res. 48, 329-334 (1988).
23. Plunkett W, Iacoboni S, Estey E et al. Pharmacologically directed ara-C therapy for refractory leukemia. Semin. Oncol. 12, 20-30 (2003).
24. Estey E, Plunkett W, Dixon D et al. Variable predicting response to high-dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1, 580-583 (1987).
25. Cooper T, Agus M, Nowak B, Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother. Pharmacol. 55, 361-368 (2005).
26. Moufarij M, Sampath D, Keating M, Plunkett W. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood 108, 4187-4193 (2006).
27. Jeha S, Gandhi V, Chan K et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 103, 784-789 (2006).
28. Jeha S, Gaynon P, Razzouk B et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J. Clin. Oncol. 24, 1917-1923 (2006).
29. Foran J, Faderl S, Wetzler M et al. A Phase II, open-label study of clofarabine in adult patients with refractory or relapsed acute myelogenous leukemia. Proc. Am. Soc. Clin. Oncol. 22, 587 (2003).
30. Faderl S, Garcia-Manero G, Ravandi F et al. Oral and intravenous clofarabine for patients with myelodysplastic syndrome. Blood 112, 222 (2008).
31. Faderl S, Gandhi V, O'Brien S et al. Results of a Phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory leukemias. Blood 105, 940-947 (2005).
32. Faderl S, Gandhi V, Verstovsek S et al. Clofarabine plus cytarabine combination is active in newly diagnosed patients > = age 50 with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Blood 104, 875 (2004).
33. Agura E, Berryman R, Brougher L et al. Phase II study of clofarabine and cytosine arabinoside in adult patients with relapsed AML and in elderly patients with untreated AML who are at high risk of anthracycline toxicity. Blood 108, 552a (2006).
34. Yamauchi T, Nowak B, Keating M, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin. Cancer Res. 7, 3580-3589 (2001).
35. Szmigielska-Kaplon A, Ciesielska E, Szmiegiero L, Robak T. Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro. Eur. J. Haematol. 68, 370-375 (2002).
36. Faderl S, Ferrajoli A, Wierda W et al. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 113, 2090-2096 (2002).
37. Burnett AK, Kell WJ, Hills RK et al. The feasibility of combining daunorubicin, clofarabine and gemtuzumab ozogamicin is feasible and effective. Blood 108, 551a (2006).
38. Karp J, Ricklis R, Greer J, Briel J, Levis M. Phase I clinical laboratory trial of clofarabine (CLO) followed by cyclophosphamide (CY) for adults with refractory acute leukemias: evidence for enhanced DNA damage. Blood 108, 555a (2006).
39. Burnett AK, Russell N, Kell JW et al. A Phase II evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy. Blood 104, S1869 (2004).
40. Burnett AK, Baccarani M, Johnson P et al. A Phase II study (Biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable. Blood 108, 130a (2006).
41. Erba HP, Kantarjian H, Claxton DF et al. Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy. Blood 112, 558 (2008).
42. Farderl S, Ravandi F, Huang X et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112, 1638-1645 (2008).